Orchard Therapeutics Future Growth
Future criteria checks 2/6
Orchard Therapeutics is forecast to grow earnings and revenue by 12.5% and 34.5% per annum respectively while EPS is expected to grow by 55.2% per annum.
Key information
12.5%
Earnings growth rate
55.2%
EPS growth rate
| Biotechs earnings growth | 28.3% |
| Revenue growth rate | 34.5% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 15 Dec 2023 |
Recent future growth updates
Recent updates
Orchard Therapeutics: Still An Attractive Merger Arbitrage Opportunity With A CVR
Jan 19Revenues Working Against Orchard Therapeutics plc's (NASDAQ:ORTX) Share Price
May 09
Is Orchard Therapeutics (NASDAQ:ORTX) A Risky Investment?
Mar 10Orchard Therapeutics: Gene Therapy For Rare Child Disease
Aug 19Orchard Therapeutics GAAP EPS of -$0.40 misses by $0.14, revenue of $4.37M beats by $1.19M
Aug 04Orchard Therapeutics: Shadow Of Former Glory
Jan 20Orchard Therapeutics: Cutting-Edge Science Beset With A Pioneer's Typical Hurdles
Aug 16Orchard Therapeutics (NASDAQ:ORTX) Has Debt But No Earnings; Should You Worry?
Jun 14What Is The Ownership Structure Like For Orchard Therapeutics plc (NASDAQ:ORTX)?
Feb 03Orchard Therapeutics appoints Braden Parker as chief commercial officer
Jan 29Orchard Therapeutics' OTL-200 wins FDA's RMAT status
Jan 14Orchard Therapeutics' OTL-103 US application for immunodeficiency disorder, pushed to 2022
Jan 12Is Orchard Therapeutics plc (NASDAQ:ORTX) Trading At A 26% Discount?
Jan 08Orchard Therapeutics' MLD gene therapy wins European nod
Dec 21Our View On Orchard Therapeutics
Dec 17Reflecting on Orchard Therapeutics' (NASDAQ:ORTX) Share Price Returns Over The Last Year
Dec 11Orchard's gene therapy shows encouraging action in a rare neurometabolic disorder study
Dec 08Orchard Therapeutics (ORTX) Investor Presentation - Slideshow
Nov 22Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 152 | -50 | -106 | N/A | 2 |
| 12/31/2025 | 97 | -75 | -148 | N/A | 2 |
| 12/31/2024 | 54 | -115 | -129 | -114 | 3 |
| 12/31/2023 | 28 | -93 | -85 | -85 | 3 |
| 9/30/2023 | 22 | -73 | -94 | -93 | N/A |
| 6/30/2023 | 21 | -85 | -93 | -87 | N/A |
| 3/31/2023 | 18 | -124 | -93 | -86 | N/A |
| 12/31/2022 | 23 | -151 | -83 | -76 | N/A |
| 9/30/2022 | 16 | -179 | -104 | -97 | N/A |
| 6/30/2022 | 12 | -168 | -100 | -96 | N/A |
| 3/31/2022 | 7 | -154 | -109 | -105 | N/A |
| 12/31/2021 | 2 | -145 | -128 | -125 | N/A |
| 9/30/2021 | 1 | -142 | -106 | -104 | N/A |
| 6/30/2021 | 2 | -126 | -115 | -114 | N/A |
| 3/31/2021 | 3 | -137 | -117 | -116 | N/A |
| 12/31/2020 | 3 | -152 | -139 | -126 | N/A |
| 9/30/2020 | 3 | -164 | -171 | -155 | N/A |
| 6/30/2020 | 3 | -180 | -197 | -181 | N/A |
| 3/31/2020 | 3 | -183 | -187 | -172 | N/A |
| 12/31/2019 | 3 | -163 | -170 | -166 | N/A |
| 9/30/2019 | 3 | -143 | -153 | -151 | N/A |
| 6/30/2019 | 2 | -140 | -131 | -130 | N/A |
| 3/31/2019 | 2 | -246 | -129 | -127 | N/A |
| 12/31/2018 | 2 | -230 | -102 | -98 | N/A |
| 9/30/2018 | 1 | -219 | -85 | -81 | N/A |
| 6/30/2018 | N/A | -198 | -63 | -59 | N/A |
| 3/31/2018 | N/A | -48 | -43 | -40 | N/A |
| 12/31/2017 | N/A | -40 | -34 | -32 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ORTX is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: ORTX is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: ORTX is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: ORTX's revenue (34.5% per year) is forecast to grow faster than the US market (8.1% per year).
High Growth Revenue: ORTX's revenue (34.5% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if ORTX's Return on Equity is forecast to be high in 3 years time